



Inflammatory and Immunological Markers in Liver Cancers

Guest Editor:

Dr. Andrea Dalbeni

Section of General Medicine C
and Liver Unit, University of
Verona, Verona, Italy

Deadline for manuscript
submissions:

closed (31 May 2024)

Message from the Guest Editor

Liver cancer (hepatocellular and colangiocharcinoma) is the second most common cause of cancer deaths worldwide.

Inflammation has been recognized as sign of cancer and is known to play an important role in the deterioration and progression of most tumors, even those that have no visible signs of inflammation and infection.

Liver inflammation is regulated by chemokines, which regulate the migration and activities of hepatocytes, Kupffer cells, hepatic stellate cells, endothelial cells, and circulating immune cells.

Emerging experimental data indicate that the presence of a preexisting intratumoral T-cell infiltration, interferon (IFN) signaling, checkpoint molecules (PD-1, PD-L1 expression) or high tumor mutational burden could favor a clinical response. In recent years, immune checkpoint inhibitors, which unleash the body's own immune response to attack tumors by targeting regulatory pathways in T cells, have shown remarkable efficacy in liver cancers.

If the relationship between inflammatory factors, immunological setting and liver cancers can be found, it may provide new directions for treatment of liver cancer.

This special issue wants to focus on these aspects.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)